These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide. Bhattacharyya S; Pal S; Chattopadhyay N Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739 [TBL] [Abstract][Full Text] [Related]
4. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Toulis KA; Anastasilakis AD; Polyzos SA; Makras P Hormones (Athens); 2011; 10(3):174-95. PubMed ID: 22001129 [TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Augustine M; Horwitz MJ Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470 [TBL] [Abstract][Full Text] [Related]
6. Anabolic therapies for osteoporosis. Uihlein AV; Leder BZ Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427 [TBL] [Abstract][Full Text] [Related]
7. Abaloparatide and the Spine: A Narrative Review. Thompson JC; Wanderman N; Anderson PA; Freedman BA Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617 [TBL] [Abstract][Full Text] [Related]
8. New anabolic therapies for osteoporosis. Minisola S; Cipriani C; Occhiuto M; Pepe J Intern Emerg Med; 2017 Oct; 12(7):915-921. PubMed ID: 28780668 [TBL] [Abstract][Full Text] [Related]
9. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089 [TBL] [Abstract][Full Text] [Related]
13. Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. Rachner TD; Hofbauer LC; Göbel A; Tsourdi E J Mol Endocrinol; 2019 Feb; 62(2):R145-R154. PubMed ID: 30389901 [TBL] [Abstract][Full Text] [Related]
14. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis]. Takeuchi Y Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591 [TBL] [Abstract][Full Text] [Related]
15. Emerging anabolic agents in the treatment of osteoporosis. Lovato C; Lewiecki EM Expert Opin Emerg Drugs; 2017 Sep; 22(3):247-257. PubMed ID: 28756709 [TBL] [Abstract][Full Text] [Related]
16. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Brixen KT; Christensen PM; Ejersted C; Langdahl BL Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497 [TBL] [Abstract][Full Text] [Related]
17. Emerging anabolic treatments in osteoporosis. Mosekilde L; Tørring O; Rejnmark L Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248 [TBL] [Abstract][Full Text] [Related]
18. Anabolic agents: what is beyond osteoporosis? Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of parathyroid hormone, parathyroid hormone-related protein, and abaloparatide on collagen 1 expression by mouse cementoblasts and mouse tooth root density. Hsu C; He Z; Le Henaff C; Partridge NC Am J Orthod Dentofacial Orthop; 2023 Mar; 163(3):378-388.e1. PubMed ID: 36543659 [TBL] [Abstract][Full Text] [Related]
20. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis. Canalis E Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]